Silencing microRNA by interfering nanoparticles in mice (scientific article)

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

Q24649633

The promises and pitfalls of RNA-interference-based therapeutics

Q24657247

MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms

Q24680714

MicroRNA-155 is induced during the macrophage inflammatory response

Q24683841

Interferon modulation of cellular microRNAs as an antiviral mechanism

Q27489711

The role of RNAi and microRNAs in animal virus replication and antiviral immunity

Q27490179

The functions of animal microRNAs

Q27860621

A microRNA polycistron as a potential human oncogene

Q27860720

Silencing of microRNAs in vivo with 'antagomirs'

Q27860891

Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs

Q27861053

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA

Q27861124

bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila

Q28131827

The diverse functions of microRNAs in animal development and disease

Q28266193

Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation

Q28268899

Control of stress-dependent cardiac growth and gene expression by a microRNA

Q28587851

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

Q29547487

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

Q29615959

LNA-mediated microRNA silencing in non-human primates

Q29615962

Illuminating the silence: understanding the structure and function of small RNAs

Q29622905

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Q34436572

MicroRNA functions in animal development and human disease

Q36285673

Cellular microRNA and P bodies modulate host-HIV-1 interactions

Q37391014

Delivery of therapeutic RNAi by nanovehicles

Q37581548

Tolerance for mutations and chemical modifications in a siRNA.

Q39698017

New hope for a microRNA therapy for liver cancer

Q39838405

Suppression of microRNA-silencing pathway by HIV-1 during virus replication

Q40166750

Potent RNAi by short RNA triggers.

Q41940226

siRNA function in RNAi: a chemical modification analysis

Q42044356

RNAi in human cells: basic structural and functional features of small interfering RNA.

Q44199577

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

Q45147309

P275

Creative Commons Attribution-NonCommercial 2.5 Generic

copyrighted

issue

language of work or name

English

Q1860

P921

main subject

nanoparticle

Q61231

microRNA

Q310899

P304

page(s)

e38

P577

publication date

2011-01-06

P1433

published in

Nucleic Acids Research

Q135122

P1476

title

Silencing microRNA by interfering nanoparticles in mice

P478

volume

Reverse relations

cites work (P2860)

Q92581957	Adenylyl cyclase‑associated protein 1‑targeted nanoparticles as a novel strategy for the treatment of metastatic non‑small cell lung cancer
Q37947912	Breast cancer and microRNAs: therapeutic impact.
Q38112723	Canonical and non-canonical barriers facing antimiR cancer therapeutics
Q42373834	Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Q26999187	Epigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectives
Q35039281	Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Q36487134	Gene regulation by non-coding RNAs
Q39351982	Interfering nanoparticles for silencing microRNAs
Q36901850	Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma
Q36037933	MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Q38002726	MicroRNA silencing and the development of novel therapies for liver disease
Q38184973	MicroRNAs and human diseases: diagnostic and therapeutic potential
Q26752710	MicroRNAs as regulators of apoptosis mechanisms in cancer
Q37381107	MicroRNAs as therapeutic targets in chemoresistance
Q34599354	MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives
Q37292279	MicroRNAs in Head and Neck Cancer
Q33880442	MicroRNAs in liver disease
Q37937737	MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality
Q24595213	Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Q37139278	Non-coding RNAs and cancer
Q30632163	Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.
Q37510967	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer
Q37478933	Progress in microRNA delivery
Q37984588	Recent trends in cancer drug resistance reversal strategies using nanoparticles
Q26777595	Role and Function of MicroRNAs in Extracellular Vesicles in Cardiovascular Biology
Q38285749	Strategies to antagonize miRNA functions in vitro and in vivo
Q34278112	The duality of oncomiR addiction in the maintenance and treatment of cancer
Q38391282	The role of hypoxia-induced miR-210 in cancer progression
Q37991391	Therapeutic modulation of miRNA for the treatment of proinflammatory lung diseases.
Q38228101	Therapeutic targeting of microRNAs: current status and future challenges
Q35828495	Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer
Q52682041	Tumor-Targeting Anti-MicroRNA-155 Delivery Based on Biodegradable Poly(ester amine) and Hyaluronic Acid Shielding for Lung Cancer Therapy.